Trial Profile
Dose escalation study to assess the safety and tolerability of sub-conjunctival injections of XG-102 in patients with post-surgery or post-traumatic intraocular inflammation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Sep 2014
Price :
$35
*
At a glance
- Drugs Brimapitide (Primary)
- Indications Ocular inflammation
- Focus Adverse reactions
- Sponsors Xigen
- 22 Sep 2014 New trial record